drug
aceclidine
Marketedupdated 3mo agoby $LENZ LENZ Therapeutics, Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying aceclidine
- phase3Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
- phase3Phase 3 Safety Study for the Treatment of Presbyopia Subjects
- phase1Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia
- phase1Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 31, 2030
~3.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Mar 15, 2044method-of-use (U-3741)US 12414942
- Oct 8, 2039method-of-use (U-3741)US 12128036
- Oct 8, 2039method-of-use (U-3741)US 12533347
- Mar 24, 2034formulationUS 10052313
- Mar 24, 2034method-of-use (U-3741)US 11179328
- Mar 24, 2034formulationUS 9844537
FDA exclusivities (1)
- Jul 31, 2030NCENew Chemical Entity (5y)3.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that